QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 780 participants.
Also called NCT07441317
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 780 participants
- Registry
-
NCT07441317
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07441317. Randomized; quadruple masking; primary purpose treatment. Start 2026-03 (anticipated); primary completion 2027-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
- Condition
- Primary Hypercholesterolemia or Mixed Hyperlipidemia
- Intervention (Drug)
- QLC7401
- Intervention (Drug)
- Placebo
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct07441317- Content hash
de9957db52b4cd9dacfaaa24e414f89a525823c7f57752e6aa256e3b3a595df9